![GW Pharmaceuticals CEO: ‘Real Science’ in Cannabis | Mad Money | CNBC thumbnail](https://i.ytimg.com/vi/CXCat4SCSt8/hqdefault.jpg)
GW Pharmaceuticals CEO: ‘Real Science’ in Cannabis | Mad Money | CNBC
Canada’s marijuana legalization may be all the rage, but one drug company has been working for years to create real cannabis-based medicine. Jim Cramer hears from GW Pharma’s CEO about…
![US Officials could be ready to crack down on cannabis craze thumbnail](https://i.ytimg.com/vi/0K4oTcjJJmk/hqdefault.jpg)
US Officials could be ready to crack down on cannabis craze
Are US border officials cracking down on the cannabis industry? Pot stocks get smoked. With CNBC’s Aditi Roy and Scott Wapner, and the Fast Money traders, Pete Najarian, Tim Seymour,…
![Inside one of the biggest cannabis investor conferences thumbnail](https://i.ytimg.com/vi/fR5ern-W-Z4/hqdefault.jpg)
Inside one of the biggest cannabis investor conferences
The cannabis buzz. Is regulation a catalyst for pot stocks? Is it time to buy? With FM trader Tim Seymour, CNBC’s Melissa Lee and the Fast Money traders, Dan Nathan,…
![How midterm elections could impact the cannabis business thumbnail](https://i.ytimg.com/vi/IzLW-gFVVx4/hqdefault.jpg)
How midterm elections could impact the cannabis business
Vivien Azer, Cowen senior research analyst, and CNBC’s Aditi Roy join ‘Squawk Alley’ to discuss how cannabis regulation could be affected by the midterm elections, specifically in Utah, North Dakota,…
![Cannabis reclassification is 'a real milestone' for the industry," says Curaleaf's Boris Jordan thumbnail](https://i.ytimg.com/vi/YAUJsiDsLdQ/hqdefault.jpg)
Cannabis reclassification is ‘a real milestone’ for the industry,” says Curaleaf’s Boris Jordan
Boris Jordan, co-founder and executive chairman of Curaleaf, joins ‘Squawk on the Street’ to discuss the significance of cannabis’ reclassification, the federal tax code around cannabis, and much more.
![Green Growth Brands CEO: Breaking into Cannabis Retail | Mad Money | CNBC thumbnail](https://i.ytimg.com/vi/oPJJjSmw5pI/hqdefault.jpg)
Green Growth Brands CEO: Breaking into Cannabis Retail | Mad Money | CNBC
He’s spent time in the C-Suite at Victoria’s Secret and DSW, and now, he’s turning his attention to cannabis. Jim Cramer finds out what retailers can bring to the table…
![Green Thumb Industries CEO: ‘Credentializing’ Cannabis | Mad Money | CNBC thumbnail](https://i.ytimg.com/vi/u7uS8RrWbuU/hqdefault.jpg)
Green Thumb Industries CEO: ‘Credentializing’ Cannabis | Mad Money | CNBC
The whole cannabis cohort has been smoking hot, but not all pot stocks are created equal. Jim Cramer checks in with the CEO of growth-focused Green Thumb Industries to try…
![Firing up the cannabis trade thumbnail](https://i.ytimg.com/vi/O4P-ZchJR90/hqdefault.jpg)
Firing up the cannabis trade
Trader Tim Seymour on why he’s long a number of cannabis stocks. With CNBC’s Courtney Reagan and the Fast Money traders, Victoria Fernandez and Delano Saporu. For access to live…
![The organization 'Smart Approaches to Marijuana' wants America to rethink legalizing cannabis thumbnail](https://i.ytimg.com/vi/vjcS1EkpCGs/hqdefault.jpg)
The organization ‘Smart Approaches to Marijuana’ wants America to rethink legalizing cannabis
Kevin Sabet, president and CEO of Smart Approaches to Marijuana, an organization leading the lobbying effort against legalization of the drug, joins “Squawk Box” to explain why his organization is…
![GW Pharma CEO on new cannabis-derived drug thumbnail](https://i.ytimg.com/vi/V-BoWVVu31c/hqdefault.jpg)
GW Pharma CEO on new cannabis-derived drug
GW Pharmaceuticals CEO Justin Gover discusses how the company secured FDA approval for its cannabis-derived drug and what it says about the future of cannabis-derived drugs.